Personalized cancer vaccines impose a manufacturing constraint that conventional batch processes were never built to meet: each dose must be designed, produced, and released for a single patient against a fixed treatment deadline. For Modified Vaccinia Ankara (MVA), the poxvirus backbone used in many viral vector cancer vaccines, that substrate has historically been primary chicken embryo fibroblasts (CEF), a biologically familiar but operationally rigid production system that resists standardization at clinical scale.
Transgene and ProBioGen announced the expansion of their existing manufacturing partnership through an additional license agreement covering ProBioGen's AGE1.CR.pIX suspension cell line. The agreement extends a collaboration first announced in November 2024, broadening Transgene's access to a cell-based MVA production platform as its individualized neoantigen therapeutic vaccine (INTV) pipeline advances through clinical trials.
CEF-based MVA production: why the egg-derived process doesn't scale
More than 570 serial passages through primary CEF generated MVA and permanently restricted its replication to avian cell substrates, which is the biological basis for both the virus's clinical safety profile and its manufacturing constraints. CEF cultures cannot be banked as a master cell bank, require fresh preparation from embryonated eggs before each production run, and carry inherent lot-to-lot variability. For a precision therapy timed to a single patient's surgical recovery, that variability is a structural problem, not a manageable one.
ProBioGen developed AGE1.CR.pIX to remove those constraints without sacrificing avian host-cell compatibility; research into MVA production has documented this primary cell limitation in detail. The cell line derives from primary cells of a duck embryo, grows only in avian cells as MVA does, and supports productive virus propagation. Its chemically defined, animal-component-free growth medium eliminates a key variable in lot release testing, and the line banks as a good manufacturing practice (GMP) master cell bank, anchoring every production batch to the same fully characterized starting material.
What makes AGE1.CR.pIX suited to personalized vaccine manufacturing
AGE1.CR.pIX is a stable, immortalized avian suspension cell line with full GMP documentation and high permissivity for poxvirus vectors including MVA. Key attributes for this application include:
- True suspension growth in commercially available, chemically defined, animal-component-free medium
- GMP master cell bank format with full characterization documentation
- Compatibility with bioreactor formats for scalable, reproducible production
- Permissivity for vaccine viruses beyond MVA, including other poxviruses and influenza strains
- Track record across multiple clinical programs, with use reported in Phase 3-stage trials
Volker Sandig, chief scientific officer at ProBioGen, explained the manufacturing rationale in company materials. "A continuous cell line qualified as a GMP master cell bank, grown in chemically defined and animal-component-free medium, means every batch begins from the same fully characterized starting material," Sandig said. "That is the foundation of a process that is reproducible, scalable and straightforward to transfer — and it lets our partners focus on the virus-product rather than the cell substrate."
Published process intensification studies pairing AGE1.CR.pIX with perfusion bioreactor technology have achieved very high MVA yields, with infectious titers of 2.1 to 16.5 x 10⁹ virions/mL, far above outputs from conventional batch processes on primary cells. For individualized vaccine programs, that throughput headroom matters because each patient-specific batch must hit clinical-grade viral titers from a manufacturing run sized for one person, not a population.
TG4050 and TG4070: Transgene's myvac programs in active clinical development
Transgene's myvac platform has two INTVs in active clinical development, each built on the MVA vector and each moving toward cell-line-based manufacturing. TG4050, the lead program, encodes up to 30 patient-specific predicted tumor neoantigens and met all Phase 1 trial endpoints as a monotherapy. Phase 1 data published on medRxiv in January 2026 showed long-lasting neoantigen-specific immune responses sustained for up to two years, with all treated patients disease-free at two-year follow-up.
Phase 2 enrollment in the same randomized multicenter trial closed at 38 patients, with Phase 2 data readout planned by the end of Q1 2028. TG4050 targets human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC); Transgene has cited the roughly one-third recurrence rate within two years of surgery as the rationale for adjuvant immunotherapy in this setting, including in patients who have already received checkpoint inhibitors. Transgene produced TG4050 using CEF for the Phase 1 run.
TG4070, the second INTV candidate, extends the myvac platform into non-small cell lung cancer (NSCLC). Transgene designed TG4070 from the outset around a cell-line-based manufacturing process, integrating proprietary AI-driven neoantigen selection with AGE1.CR.pIX production to improve turnaround time, reproducibility, and scalability. A randomized Phase 1 trial in combination with nivolumab opened in June 2026, targeting patients with resected NSCLC following neoadjuvant chemoimmunotherapy.
Alessandro Riva, chairman and chief executive officer of Transgene, said the expanded license fits the platform's direction. "This additional license reflects our confidence in the technology to prepare for future clinical needs at scale," Riva said.
How AGE1.CR.pIX compares to other MVA production substrates
Cell substrates for MVA production differ substantially in regulatory readiness, batch consistency, and fit with personalized vaccine timelines. CEF supports efficient MVA replication but provides no bankable starting material, while baby hamster kidney cells (BHK-21) and Vero cells both show semi-permissive MVA replication that limits their utility for high-titer poxvirus production. AGE1.CR.pIX, as a GMP-banked, chemically defined suspension line derived from a continuous immortalized cell bank, removes those constraints and anchors every batch to the same characterized starting point.
| Manufacturing substrate | Cell bank format | Medium | MVA permissivity | Regulatory status |
|---|---|---|---|---|
| Primary chicken embryo fibroblasts (CEF) | None; prepared fresh per batch | Serum-containing | High | Historical standard; variability challenges |
| AGE1.CR.pIX (duck suspension) | GMP master cell bank | Chemically defined, animal-component-free | High | GMP-compliant; used in Phase 3 programs |
| BHK-21 (baby hamster kidney) | Master cell bank possible | Serum or defined | Semi-permissive | Used for some viral vaccines; limited MVA yield |
| Vero (African green monkey) | Master cell bank | Serum or defined | Semi-permissive | Broadly used for viral vaccines; not optimal for MVA |
Regulatory pressure reinforces the shift toward continuous lines. Health authorities apply a "defined risk" framework to production substrates, favoring fully characterized, immortalized lines with documented adventitious agent testing over primary cell preparations that require fresh risk assessment before each use. GeoVax Labs signed a commercial AGE1.CR.pIX license in 2023 for its MVA-based portfolio, and Nouscom's Nous-209 cancer vaccine reached randomized Phase 2 trials using AGE1.CR.pIX-manufactured MVA vector.
Cell-line manufacturing positions myvac for clinical-scale expansion
To overcome the lot-to-lot variability and scaling limits of traditional egg-derived manufacturing, Transgene is expanding its partnership with ProBioGen to use the AGE1.CR.pIX suspension cell line for its MVA-based personalized cancer vaccines. This GMP-banked, chemically defined production platform allows Transgene to rapidly and reproducibly manufacture patient-specific doses for its active clinical programs, TG4050 and TG4070. By securing this scalable manufacturing backbone, Transgene is positioned to meet evolving regulatory standards and support its upcoming clinical trial readouts in 2026 and 2028.
This article is based on a press release issued by Transgene and was produced under Drug Discovery News' AI Editorial Guidelines.
